ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health care cost"

  • Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting

    Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis

    Joseph Tkacz1, Edward Lee2, Robert Low2, Jeffrey Stark2, Mohamed Yassine2 and Brenna Brady1, 1Health Analytics LLC, Columbia, MD, 2UCB Pharma, Smyrna, GA

    Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
  • Abstract Number: 1043 • 2017 ACR/ARHP Annual Meeting

    Comparison of the Costs for Hyaluronic Acid and Total Knee Arthroplasty in the Treatment of OA for the Blue Cross/Blue Shield Patient Population

    Kevin Ong1, Faizan Niazi2, Edmund Lau3, Peter Shaw2 and Steven Kurtz1, 1Exponent, Inc., Philadelphia, PA, 2Ferring Pharmaceuticals, Inc., Parsippany, NJ, 3Exponent, Inc., Menlo Park, CA

    Background/Purpose: Previous HA studies have focused on the Medicare population, but less is known of the treatment patterns and cost of HA relative to knee…
  • Abstract Number: 1049 • 2017 ACR/ARHP Annual Meeting

    Heart Rate Variability Testing with Autonomic Nervous System Optimization: Could It Change the Course of Spending for Rheumatoid Arthritis Patients in the U.S.? an Exploratory Minimal Model Analysis

    Marita Zimmermann1, Elisabeth Vodicka2, Andrew J Holman3,4,5 and Louis P Garrison2, 1Constants in Global Health, University of Washington, Seattle, WA, 2Consultants in Global Health, University of Washington, Seattle, WA, 3Rheumatology, Pacific Rheumatology Associates Inc PS, Seattle, WA, 4Inmedix, Normandy Park, WA, 5Pacific Rheumatology Reseach, Seattle, WA

    Background/Purpose: Autonomic nervous system (ANS) testing with heart rate variability (HRV) has been shown to predict 52-week anti-TNF therapeutic outcomes in rheumatoid arthritis (RA).1 HRV…
  • Abstract Number: 1054 • 2017 ACR/ARHP Annual Meeting

    Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis

    Nina Mars1,2, Anne M Kerola2,3, Markku J Kauppi4,5, Matti Pirinen1, Outi Elonheimo6 and Tuulikki Sokka-Isler7, 1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 2University of Helsinki, Helsinki, Finland, 3Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 4School of Medicine, University of Tampere, Tampere, Finland, 5Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, 6FCG Finnish Consulting Group Ltd., Helsinki, Finland, 7Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland

    Background/Purpose: Utilization patterns in rheumatoid arthritis (RA) are complex. For targeted interventions, patients with special healthcare needs should be recognized. Our aim was to explore…
  • Abstract Number: 1561 • 2017 ACR/ARHP Annual Meeting

    Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Biologic-NaïVe Psoriatic Arthritis

    Vibeke Strand1, M. Elaine Husni2, Rakesh Singh3, Keith Betts4, Yan Song5, Jenny Griffith3 and Arijit Ganguli3, 1Stanford University, Palo Alto, CA, 2Cleveland Clinic, Cleveland, OH, 3AbbVie Inc., North Chicago, IL, 4Analysis Group, Inc., Los Angeles, CA, 5Analysis Group, Inc., Boston, MA

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory condition characterized by peripheral arthritis and psoriatic skin lesions requiring therapies that control both skin and joint symptoms.…
  • Abstract Number: 2260 • 2017 ACR/ARHP Annual Meeting

    Communication Strategies Are Highly Important to Avoid Nocebo Effect When Performing Non-Medical Switch from Originator Product to Biosimilar Product: Danish Results from Applying the Parker Model a Qualitative 3-Step Research Model

    Tanja Schjødt Jørgensen1, Marie Skougaard1, Hans Christian Asmussen2,3, Anne Lee4, Peter C. Taylor5, Henrik Gudbergsen1 and Lars Erik Kristensen1, 1The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, 2NATiON, Copenhagen, Denmark, 3Communication IKH, Roskilde University, Roskilde, Denmark, 4University of Southern Denmark, Odense, Denmark, 5University of Oxford Botnar Research Centre, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

    Background/Purpose: Introducing a non-medical switch from originator to a biosimilar product in the management of chronic arthritis, i.e. switching patients in remission or low disease…
  • Abstract Number: 2812 • 2017 ACR/ARHP Annual Meeting

    Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis

    Christopher F Bell1, Julie Priest2,3, Marni Stott-Miller4, Hong Kan5, Justyna Amelio6, Xue Song7, Brendan Limone7, Virginia Noxon7 and Karen H. Costenbader8, 1GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, 2GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, 3US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, 4GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, 5Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 6GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, 7Truven Health Analytics, an IBM company, Ann Arbor, MI, 8Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. There is…
  • Abstract Number: 1231 • 2016 ACR/ARHP Annual Meeting

    Impact of Comorbidity on Health-Related Quality of Life and Healthcare Expenditure in Patients with Rheumatoid Arthritis

    Eric Nyarko1 and J An2, 1College of Pharmacy, Western University of Health Sciences, Pomona, CA, 2Western University of Health Sciences, Pomona, CA

    Background/Purpose: Rheumatoid Arthritis (RA) is known to be associated with an increased risk of comorbidity, premature mortality, and disability. We investigated the effect of comorbidity…
  • Abstract Number: 1236 • 2016 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs

    Karina Raimundo1, Amanda Farr2, Ashley Cole3 and Jeffrey J. Swigris4, 1Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, 2Truven Health Analytics, Cambridge, MA, 3Truven Health Analytics, Bethesda, MD, 4Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO

    Background/Purpose: Interstitial lung disease (ILD) is commonly associated with rheumatoid arthritis (RA) and can have significant morbidity and mortality. The objective was to calculate the…
  • Abstract Number: 1238 • 2016 ACR/ARHP Annual Meeting

    Assessment of Mortality and Healthcare Costs Associated with Systemic Sclerosis with and without Lung Involvement

    Karina Raimundo1, Amanda Farr2, Ashley Cole3 and Aryeh Fischer4, 1Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, 2Truven Health Analytics, Cambridge, MA, 3Truven Health Analytics, Bethesda, MD, 4Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Patients with systemic sclerosis (SSc) are at high risk of developing interstitial lung disease (ILD) and/or pulmonary hypertension (PH).  These two lung manifestations are…
  • Abstract Number: 1240 • 2016 ACR/ARHP Annual Meeting

    A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis

    Nina Mars1, Anne M Kerola2, Markku J Kauppi3,4, Outi Elonheimo5,6, Santeri Huvinen5,6 and Tuulikki Sokka-Isler7,8, 1University of Helsinki, Helsinki, Finland, 2Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 3School of Medicine, University of Tampere, Tampere, Finland, 4Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, 5Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, 6FCG Finnish Consulting Group Ltd., Helsinki, Finland, 7Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, 8RAID working group for EULAR, Zurich, Switzerland

    Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare costs, but little is known about how the costs compare to other chronic rheumatic diseases. We…
  • Abstract Number: 1248 • 2016 ACR/ARHP Annual Meeting

    Access to Care: The Patient Perspective from the 2015 ACR/ARHP Workforce Study

    Seetha Monrad1, Lisa Imundo2, Daniel Battafarano3 and Marcia Ditmyer4, 1Internal Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, 2Pediatrics, Columbia University, New York, NY, 3Medicine, San Antonio Military Medical Center, San Antonio, TX, 4University of Nevada, Las Vegas, NV

    Background/Purpose: The 2015 Workforce Study (WFS) sought to expand our current understanding of the rheumatology workforce utilizing an integrated, patient-centered approach to workforce modeling. Primary…
  • Abstract Number: 2234 • 2016 ACR/ARHP Annual Meeting

    Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis

    Sergio Schwartzman1, Yunfeng Li2, Huanxue Zhou3, Vivian Herrera2 and Jacqueline B. Palmer2, 1Hospital for Special Surgery, New York, NY, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3KMK Consulting Inc, East Hanover, NJ

    Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2 Affiliations: 1Hospital for Special Surgery, New York, NY, US; 2Novartis Pharmaceuticals Corporation, East Hanover,…
  • Abstract Number: 3152 • 2016 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis (RA): Premature Use of Biologics Accelerating in United States (US)

    James R. O'Dell1, Stanley B. Cohen2, J Carter Thorne3 and Ted R Mikuls4, 1Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Metroplex Clinical Research Center, Dallas, TX, 3Southlake Regional Health Centre, Newmarket, ON, Canada, 4Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The treatment of RA has changed dramatically in the past several decades with the advent of a large number of new biologic agents as…
  • Abstract Number: 104 • 2016 ACR/ARHP Annual Meeting

    Incremental Direct Expenditures Due to Osteoarthritis: A Nationally Representative Study Using Medical Expenditure Panel Survey Data

    Jyothi Menon, Purdue University, West Lafayette, IN

    Background/Purpose:  Osteoarthritis is characterized by symptoms related to abnormalities in joints, subchondral bones and periarticular structures. In the United States, it was estimated that twenty-seven…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology